Skip to main content

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q1 2023

Holdings as of Mar 31, 2023, filed May 15, 2023. Long positions only; changes compare share counts with Q4 2022.

Institution overview
Positions
63
+9 vs. Q4 2022
Portfolio value
$260.2M
+$42.0M (+19.3%) vs. Q4 2022
Filed
May 15, 2023
SEC
Holdings of Affinity Asset Advisors, LLC in Q1 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
SCLXScilex Holding CoCOM463$3.80K<0.1%00.0%UnchangedHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$12.3K<0.1%+75,000New–
SCLXWScilex Holding Co*W EXP 11/10/20218,099$19.0K<0.1%00.0%UnchangedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/20237,000$68.5K<0.1%+37,000NewHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$269.6K0.1%00.0%Unchanged–
Pieris Pharmaceuticals Inc720795103COM306,950$299.6K0.1%+306,950New–
NUVBNuvation Bio Inc.COM CL A250,000$415.0K0.2%00.0%UnchangedHistory
NLS Pharmaceutics LtdH57830103SHS344,089$519.6K0.2%+344,089New–
PBYIPuma Biotechnology, Inc.COM177,349$548.0K0.2%+177,349NewHistory
ROIVRoivant Sciences Ltd.SHS100,000$738.0K0.3%+100,000NewHistory
MISTMilestone Pharmaceuticals Inc.COM199,382$785.6K0.3%+99,382+99.4%AddedHistory
FHTXFoghorn Therapeutics Inc.COM136,771$848.0K0.3%+26,780+24.3%AddedHistory
JSPRJasper Therapeutics, Inc.COM476,948$863.3K0.3%+476,948NewHistory
BCABBioAtla, Inc.COM325,000$871.0K0.3%+175,000+116.7%AddedHistory
THRXTheseus Pharmaceuticals, Inc.COM98,221$872.2K0.3%+98,221NewHistory
MLYSMineralys Therapeutics, Inc.COM62,500$978.8K0.4%+62,500NewHistory
PNTPOINT Biopharma Global Inc.COM149,586$1.09M0.4%−153,632−50.7%ReducedHistory
ADCTADC Therapeutics SASHS600,000$1.17M0.4%+600,000NewHistory
NARIInari Medical, Inc.Stock20,000$1.23M0.5%−70,000−77.8%ReducedHistory
LIANYLianBioSPONSORED ADS650,000$1.27M0.5%00.0%UnchangedHistory
NRIXNurix Therapeutics, Inc.COM150,000$1.33M0.5%+70,000+87.5%AddedHistory
Intrexon Corp46122TAA0NOTE 3.500% 7/0–$1.47M0.6%–––
COGTCogent Biosciences, Inc.COM143,064$1.54M0.6%−50,000−25.9%ReducedHistory
VINCVincerx Pharma, Inc.COM NEW1,492,771$1.55M0.6%00.0%UnchangedHistory
KALVKalVista Pharmaceuticals, Inc.COM208,292$1.64M0.6%+20,000+10.6%AddedHistory
KPTIKaryopharm Therapeutics Inc.COM460,979$1.79M0.7%−200,285−30.3%ReducedHistory
CLDXCelldex Therapeutics, Inc.COM NEW50,000$1.80M0.7%−60,000−54.5%ReducedHistory
ALPNAlpine Immune Sciences, Inc.COM247,891$1.91M0.7%00.0%UnchangedHistory
HZNPHorizon Therapeutics Public Ltd CoSHS20,000$2.18M0.8%−25,000−55.6%ReducedHistory
KRTXKaruna Therapeutics, Inc.COM12,500$2.27M0.9%+12,500NewHistory
MIRMMirum Pharmaceuticals, Inc.COM95,000$2.28M0.9%+55,000+137.5%AddedHistory
APLSApellis Pharmaceuticals, Inc.COM35,000$2.31M0.9%+35,000NewHistory
PCVXVaxcyte, Inc.COM62,223$2.33M0.9%+2,223+3.7%AddedHistory
BMRNBiomarin Pharmaceutical IncCOM25,000$2.43M0.9%−55,000−68.8%ReducedHistory
LNTHLantheus Holdings, Inc.Stock30,244$2.50M1.0%−30,386−50.1%ReducedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS684,127$2.63M1.0%+223,799+48.6%AddedHistory
Esperion Therapeutics Inc Ne29664WAB1NOTE 4.000%11/1–$3.01M1.2%–––
ETNB89bio, Inc.COM200,000$3.05M1.2%+200,000NewHistory
XENEXenon Pharmaceuticals Inc.COM90,000$3.22M1.2%+40,000+80.0%AddedHistory
ARGXArgenx SESPONSORED ADR10,750$4.01M1.5%+5,750+115.0%AddedHistory
SGENSeagen Inc.COM20,000$4.05M1.6%+15,000+300.0%AddedHistory
AZNAstraZeneca PLCSPONSORED ADR60,000$4.16M1.6%00.0%UnchangedHistory
ASNDAscendis Pharma A/SSPONSORED ADR40,000$4.29M1.6%−30,997−43.7%ReducedHistory
INZYInozyme Pharma, Inc.COM751,796$4.31M1.7%+251,796+50.4%AddedHistory
KURAKura Oncology, Inc.COM357,287$4.37M1.7%+88,540+32.9%AddedHistory
MORFMorphic Holding, Inc.COM135,863$5.11M2.0%−145,058−51.6%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM320,000$5.31M2.0%+320,000NewHistory
ACLXArcellx, Inc.COMMON STOCK202,834$6.25M2.4%−37,309−15.5%ReducedHistory
Bellus Health Inc New07987C204COM NEW881,329$6.35M2.4%+307,651+53.6%Added–
ATXSAstria Therapeutics, Inc.COM529,369$7.04M2.7%+56,887+12.0%AddedHistory
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$7.12M2.7%–––
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$7.41M2.8%–––
ESTAEstablishment Labs Holdings Inc.COM113,224$7.67M2.9%−77,543−40.6%ReducedHistory
CYTKCytokinetics IncCOM NEW221,463$7.79M3.0%+133,862+152.8%AddedHistory
VTYXVentyx Biosciences, Inc.COM260,008$8.71M3.3%+19,385+8.1%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS452,821$9.09M3.5%+140,323+44.9%AddedHistory
CERECerevel Therapeutics Holdings, Inc.COM380,000$9.27M3.6%+165,000+76.7%AddedHistory
CBAYCymaBay Therapeutics, Inc.COM1,083,118$9.44M3.6%−60,413−5.3%ReducedHistory
VKTXViking Therapeutics, Inc.COM622,249$10.4M4.0%+272,249+77.8%AddedHistory
MRKMerck & Co., Inc.Stock120,000$12.8M4.9%+120,000NewHistory
RXDXPrometheus Biosciences, Inc.COM150,000$16.1M6.2%+75,000+100.0%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM93,000$22.5M8.7%+23,000+32.9%AddedHistory
KDNYChinook Therapeutics, Inc.COM976,021$22.6M8.7%+157,986+19.3%AddedHistory

Options (11)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q1 2023
SecurityClassPutsCalls
SPYSPDR S&P 500 ETF TrustETF–$18.4M
BBIOBridgeBio Pharma, Inc.COM$6.46M–
MRNAModerna, Inc.Stock–$5.38M
AZNAstraZeneca PLCSPONSORED ADR–$3.47M
VRDNViridian Therapeutics, Inc.COM–$2.56M
NVAXNovavax IncCOM NEW$2.40M–
VKTXViking Therapeutics, Inc.COM$1.56M–
ACRSAclaris Therapeutics, Inc.COM–$1.04M
ESPREsperion Therapeutics, Inc.COM$556.5K–
ETNB89bio, Inc.COM–$551.3K
CBIOCrescent Biopharma, Inc.COM$378.0K–

Sold out since Q4 2022 (6)

Positions held at the end of Q4 2022 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q4 2022
SecurityClassShares in Q4 2022Value in Q4 2022% of portfolio in Q4 2022History
RCKTRocket Pharmaceuticals, Inc.COM258,115$5.05M2.3%History
SNDXSyndax Pharmaceuticals IncCOM100,000$2.54M1.2%History
IOVAIovance Biotherapeutics, Inc.COM375,000$2.40M1.1%History
DYNDyne Therapeutics, Inc.COM92,170$1.07M0.5%History
CNTXContext Therapeutics Inc.COM883,654$583.7K0.3%History
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$2.93K<0.1%–